Lucas Vieira Lacerda Pires

Lucas Vieira Lacerda Pires

Auto-generated profile, based on publicly available information

Lucas Vieira Lacerda Pires

Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
LPLucas Vieira Lacerda Pires
Lucas Vieira Lacerda Pires
RBRenata de Almeida Bordim
Renata de Almeida Bordim
MMMaria Beatriz Rabelo Maciel
Maria Beatriz Rabelo Maciel
ATAna Cristina Sayuri Tanaka
Ana Cristina Sayuri Tanaka
GYGuilherme Lopes Yamamoto
Guilherme Lopes Yamamoto
DBDebora Romeo Bertola
Debora Romeo Bertola

1 November 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
LPLucas Vieira Lacerda Pires
Lucas Vieira Lacerda Pires
RRRogério Lemos Ribeiro
Rogério Lemos Ribeiro
ASAdriana Modesto de Sousa
Adriana Modesto de Sousa
BLBianca Linnenkamp
Bianca Linnenkamp
SPSue Ellen Pontes
Sue Ellen Pontes
CKChong Ae Kim
Chong Ae Kim
Background: Williams-Beuren syndrome is a multisystemic disorder caused by a microdeletion of the 7q11.23 region. Although familial cases with autosomal dominant inheritance have been reported, the vast majority are sporadic. Objective: To investigate the main complaints and clinical findings of patients with Williams-Beuren syndrome. Methods: A total of 757 parents of patients registered in the Brazilian Association of Williams-Beuren Syndrome (ABSW) received a questionnaire via WhatsApp from March to July 2017. Results: In total, 229 parents answered the survey. Age of diagnosis ranged from 2 days to 34 years (median: 3 years). The main clinical findings reported by the parents were abdominal colic (83.3%), failure to thrive (71.5%), feeding difficulty in the first year (68.9%), otitis (56.6%), urinary tract infections (31.9%), precocious puberty (27.1%) and scoliosis (15.9%). Cardiac defects were present in 66% of patients, and the most frequent defect was supravalvular aortic stenosis (36%). Arterial hypertension was reported in 23%. Hypercalcemia was reported in 10.5% of patients, mainly during the first year of life. Hyperacusis and hypersociability were common complaints (both present in 89%). Other behavioral and neuropsychiatric symptoms reported by the parents included attention deficit (89%), anger crises (83%), excessive fear (66%), depression (64%), anxiety (67%) and hypersexuality (33%). The most common complaints were hypersensitivity to sounds, talkative personality, emotional dependence and learning difficulties. In 98.3%, the parents denied family history. Conclusions: Williams-Beuren syndrome requires close follow-up with different medical specialties due to their variable clinical comorbidities, including language and school learning difficulties, behavioral and psychiatric problems.

2 August 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LRLetícia Alves da Rocha
Letícia Alves da Rocha
LPLucas Vieira Lacerda Pires
Lucas Vieira Lacerda Pires
GYGuilherme Lopes Yamamoto
Guilherme Lopes Yamamoto
JCJosé Ricardo Magliocco Ceroni
José Ricardo Magliocco Ceroni
RHRachel Sayuri Honjo
Rachel Sayuri Honjo
DBDébora Romeo Bertola
Débora Romeo Bertola

30 April 2025 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
LPLucas Vieira Lacerda Pires
Lucas Vieira Lacerda Pires
VCVinícius Machado Correia
Vinícius Machado Correia
LLLayara Fernanda Vicente Pereira Lipari
Layara Fernanda Vicente Pereira Lipari
FAFernanda Almeida Andrade
Fernanda Almeida Andrade
FFFábio Fernandes
Fábio Fernandes
JKJose Krieger
Jose Krieger
The MYH7 gene, which encodes the beta-myosin heavy chain, is a critical component in the structural and functional integrity of cardiac and skeletal muscle cells. Variants in MYH7 are among the most common genetic causes of cardiomyopathies, particularly hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and have also been implicated in restrictive cardiomyopathy (RCM) and left ventricular hypertrabeculation (LVHT). This review explores the molecular mechanisms by which MYH7 variants lead to these diverse phenotypes, focusing on the genotype-phenotype correlations [...] Abstract The MYH7 gene, which encodes the beta-myosin heavy chain, is a critical component in the structural and functional integrity of cardiac and skeletal muscle cells. Variants in MYH7 are among the most common genetic causes of cardiomyopathies, particularly hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and have also been implicated in restrictive cardiomyopathy (RCM) and left ventricular hypertrabeculation (LVHT). This review explores the molecular mechanisms by which MYH7 variants lead to these diverse phenotypes, focusing on the genotype-phenotype correlations

1 January 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
GRGiovanna Napolitano Pereira Ribeiro
Giovanna Napolitano Pereira Ribeiro
LLLayara Fernanda Vicente Pereira Lipari
Layara Fernanda Vicente Pereira Lipari
PSPaula Mendonça Senra
Paula Mendonça Senra
LPLucas Vieira Lacerda Pires
Lucas Vieira Lacerda Pires
MMMarjorie Hayashida Mizuta
Marjorie Hayashida Mizuta
JKJosé Eduardo Krieger
José Eduardo Krieger
Resumo A doença de Danon é uma doença rara ligada ao cromossomo X, causada por variantes patogênicas ou provavelmente patogênicas no gene da proteína 2 da membrana associada ao lisossomo (LAMP2). Manifesta-se principalmente como cardiomiopatia hipertrófica, miopatia, deficiência intelectual e retinopatia, sendo que os homens geralmente apresentam um fenótipo mais grave e de início precoce. A fisiopatologia da doença de Danon está ligada à autofagia defeituosa devido à deficiência de LAMP2, levando ao acúmulo de vacúolos cheios de glicogênio dentro dos cardiomiócitos e outros tecidos. Isso resulta em hipertrofia cardíaca progressiva, anormalidades de condução e eventual insuficiência cardíaca, frequentemente necessitando de transplante cardíaco. O envolvimento da musculatura esquelética é comum em homens, enquanto o comprometimento cognitivo é observado em ambos os sexos, embora mais prevalente em homens. O diagnóstico é desafiador devido à raridade da doença e à apresentação variável, o que destaca a necessidade de uma abordagem multidisciplinar, incluindo testes genéticos para um diagnóstico definitivo. Os testes genéticos devem ser realizados somente após aconselhamento genético adequado. O diagnóstico diferencial deve ser considerado quando há suspeita de doença de Danon, dependendo dos sinais e sintomas, incluindo doenças como a doença de Fabry, a síndrome PRKAG2, a doença de Pompe, entre outras. As estratégias de tratamento atuais focam no alívio dos sintomas, sendo o transplante cardíaco uma intervenção crucial para casos avançados. Terapias emergentes, como a terapia gênica direcionada ao gene LAMP2, podem auxiliar na alteração da progressão da doença. Esta revisão oferece uma visão abrangente da doença de Danon, abordando suas manifestações clínicas, mecanismos subjacentes, desafios diagnósticos e potenciais abordagens terapêuticas para melhorar os resultados. Nosso objetivo é aumentar o reconhecimento da doença de Danon para que a prevenção de possíveis complicações e o diagnóstico precoce se tornem viáveis, levando, em última análise, a desfechos mais favoráveis para os pacientes.

5 August 2024 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
SFSilas Ramos Furquim
Silas Ramos Furquim
LLLayara Fernanda Vicente Pereira Lipari
Layara Fernanda Vicente Pereira Lipari
FAFernanda Almeida Andrade
Fernanda Almeida Andrade
VCVinícius Machado Correia
Vinícius Machado Correia
NONatalia Quintella Sangiorgi Olivetti
Natalia Quintella Sangiorgi Olivetti
JKJose Krieger
Jose Krieger
Cardiomyopathy is characterized by structural and functional abnormalities in the heart muscle that are not influenced by coronary disease, hypertension, valve disease, or congenital heart defects. Genetic testing, which helps diagnose the molecular bases of cardiomyopathy, can affect prognostication and clinical decisions. Recent guidelines advocate classifying cardiomyopathies based on phenotypic categories, which encompass a range of clinical presentations, underlying causes, and outcomes. Beyond deepening our grasp of the disease, genetic testing can distinguish between diseases with similar presentations, known [...] Abstract Cardiomyopathy is characterized by structural and functional abnormalities in the heart muscle that are not influenced by coronary disease, hypertension, valve disease, or congenital heart defects. Genetic testing, which helps diagnose the molecular bases of cardiomyopathy, can affect prognostication and clinical decisions. Recent guidelines advocate classifying cardiomyopathies based on phenotypic categories, which encompass a range of clinical presentations, underlying causes, and outcomes. Beyond deepening our grasp of the disease, genetic testing can distinguish between diseases with similar presentations, known